Ocrelizumab now available for those with primary progressive MS

10 May, 2019 | Posted in:

Ocrelizumab, the first disease-modifying treatment (DMT) to be proven in slowing down the progression of primary progressive multiple sclerosis (PPMS), has finally been signed off for use at a clinical level. The DMT has been licensed for relapsing-remitting (RR) MS for almost a year, but despite being the first drug to show efficacy in the […]

Continue Reading »

Brain Awareness Week 2019: multiple sclerosis

12 March, 2019 | Posted in: ,

Brain Awareness Week (BAW) coordinated by the Dana Foundation, is an opportunity for partners around the globe to share their research and educate people of all ages and backgrounds about the brain and the promise of brain research. The Neurology Academy, as neurological educators, are keen to cover as broad a picture of a condition as possible, from physiological […]

Continue Reading »

Consensus guidelines reached regarding pregnancy and MS

15 January, 2019 | Posted in: ,

A set of guidelines on multiple sclerosis (MS) and pregnancy have been produced for the UK, supported by the Association of British Neurologists. The first of their kind, the guidance covers all elements of care related to pregnancy for those living with MS, from pre-pregnancy support to management of medication during pregnancy, birth-related guidance and […]

Continue Reading »

Cannabis based products in multiple sclerosis

18 December, 2018 | Posted in:

On the 1 November 2018, it became legal for doctors to prescribe cannabis based drugs, which occurred with widespread media coverage. But, there are limitations to this ruling, which have not been fully explained to the public, and many neurology departments are receiving queries from patients who are requesting prescriptions for cannabis based drugs from […]

Continue Reading »